



## PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

2nd April 2014 - New clinical trial

### ISRADIPINE BEING TESTED FOR PARKINSON'S DISEASE

After proving safe in a study funded by The Michael J.Fox Foundation, Isradipine is moving to Phase III testing of its effect on Parkinson's Disease thanks to a \$23 million grant from the National Institutes of Health. They hope to enrol more than 300 participants at 56 clinical sites throughout North America. For more information go to the Michael J.Fox Foundation : <https://www.michaeljfox.org/foundation/news-detail.php?podcast-drug-that-may-slow-parkin-son-progression-granted-23-million-from-nih-for-phase-iii>



Isradipine is a calcium channel blocker that is marketed as Dynacirc. Dynacirc is a drug that is prescribed to treat high blood pressure. For more information concerning Dynacirc go to Medline Plus :

<http://www.nlm.nih.gov/medlineplus/druginfo/meds/a693048.html>

The basis for the clinical trial is that data from large studies found that there was a lower incidence of Parkinson's Disease among those people who took Isradipine.

However, when Isradipine was tested in Phase II clinical trials in people who had Parkinson's Disease Isradipine caused side effects. The most common adverse events were peripheral edema and dizziness. Isradipine also failed to have any significant effect on Parkinson's Disease symptoms. For more information go to the Phase II clinical trial outcome :

[https://www.michaeljfox.org/foundation/grant-detail.php?grant\\_id=486](https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=486)

In order to treat Parkinson's Disease effectively dopamine formation must be increased but, even in theory, calcium channel blockers can not do that.

<http://www.viartis.net/parkinsons.disease/news/140402.pdf>

[mail@viartis.net](mailto:mail@viartis.net)

©2014 Viartis